Shares of Genzyme Corp. fell 7 percent Tuesday after the Cambridge, Mass.-based firm said it received a complete response letter from the FDA for its application for Pompe disease treatment Lumizyme (alglucosidase alfa), which is the 2,000 L bioreactor scale version of the firm's Myozyme. (BioWorld Today) Read More
